Merck KGaA selling manufacturing site, allergy drugs to Dermapharm

Merck KGaA's Allergopharma manufacturing site includes a plant opened in 2017 for expansion into China. (Merck KGaA)

It's out with the old and in with the new for Merck KGaA. The German drugmaker is selling a manufacturing site and its Allergopharma allergy drug business as it focuses on new specialty drugs.

The sale comes just three years after Merck opened a new manufacturing facility for an Asia expansion of its allergy drug business. Merck is selling the site and portfolio of drugs to German compatriot Dermapharm, which focuses on generic allergy medications. Terms of the deal, which is slated to close in the second quarter, were not disclosed, but Merck said Allergopharma had 2018 sales of about €88 million. 

RELATED: Merck KGaA antes up €250M to bridge R&D with manufacturing


Veeva 2020 Unified Clinical Operations Survey

We believe you have the knowledge and expertise to make this year's Veeva 2020 Clinical Operations Report even more robust and insightful than the last. Please take a moment to share your opinion in this 10-minute survey. All qualified respondents will be entered to win a $500 Amazon gift card.

The business includes a site in Reinbek, Germany, near Hamburg and the portfolio of therapeutic and diagnostic products Merck says treats type 1 allergies like hay fever. It markets the products in Europe and Asia. 

The deal will not include Merck’s adrenaline autoinjector development project for the treatment of anaphylaxis. Merck said the deal is in line with its moves to focus on “difficult-to-treat diseases.”

RELATED: Merck KGaA opens new Allergopharma plant in Germany

Merck in 2017 opened new Allergopharma manufacturing plant at the Reinbek site. The €42 million ($44.4 million), 6,000-square-meter (64,583-square-foot) facility was built at the current Allergopharma complex in Reinbek for the business expansion into China. At the time, Merck said the Reinbek site had about 500 employees. 

Grünwald-based Dermapharm sells off-patent branded medicines for selected markets in Germany. Its primary production site is in Brehna near Leipzig. The company says it has more than 900 marketing authorizations for about 250 active ingredients that are commercialized either as medicines, food supplements or supplements to balanced diets.

Suggested Articles

Only months removed from a gamechanging label expansion for Vascepa, Amarin is scrambling after a district judge invalidated the drug's key patents.

Move over, Roche. There’s a new small-cell lung cancer therapy on the scene, and it belongs to AstraZeneca.

Fujifilm says it is prepared to ramp up production of Avigan for any country that wants to try it as a potential treatment for COVID-19.